|
1
|
McMaster ML, Goldstein AM, Bromley CM,
Ishibe N and Parry DM: Chordoma: incidence and survival patterns in
the United States, 1973–1995. Cancer Causes Control. 12:1–11.
2001.
|
|
2
|
Anson KM, Byrne PO, Robertson ID, Gullan
RW and Montgomery AC: Radical excision of sacrococcygeal tumours.
Br J Surg. 81:460–461. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tzortzidis F, Elahi F, Wright D, Natarajan
SK and Sekhar LN: Patient outcome at long-term follow-up after
aggressive microsurgical resection of cranial base chordomas.
Neurosurgery. 59:230–237. 2006. View Article : Google Scholar
|
|
4
|
Chugh R, Tawbi H, Lucas DR, Biermann JS,
Schuetze SM and Baker LH: Chordoma: the nonsarcoma primary bone
tumor. Oncologist. 12:1344–1350. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vaupel P, Hockel M and Mayer A: Detection
and characterization of tumor hypoxia using pO2
histography. Antioxid Redox Signal. 9:1221–1235. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Majmundar AJ, Wong WJ and Simon MC:
Hypoxia-inducible factors and the response to hypoxic stress. Mol
Cell. 40:294–309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang LE, Gu J, Schau M and Bunn HF:
Regulation of hypoxia-inducible factor 1alpha is mediated by an
O2-dependent degradation domain via the
ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 95:7987–7992.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Welsh SJ, Koh MY and Powis G: The hypoxic
inducible stress response as a target for cancer drug discovery.
Semin Oncol. 33:486–497. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Semenza GL: Evaluation of HIF-1 inhibitors
as anticancer agents. Drug Discov Today. 12:853–859. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dai Y, Bae K and Siemann DW: Impact of
hypoxia on the metastatic potential of human prostate cancer cells.
Int J Radiat Oncol Biol Phys. 81:521–528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Forsythe JA, Jiang BH, Iyer NV, Agani F,
Leung SW, Koos RD and Semenz GL: Activation of vascular endothelial
growth factor gene transcription by hypoxia-inducible factor 1. Mol
Cell Biol. 16:4604–4613. 1996.PubMed/NCBI
|
|
12
|
Shyu KG, Hsu FL, Wang MJ, Wang BW and Lin
S: Hypoxia-inducible factor 1alpha regulates lung adenocarcinoma
cell invasion. Exp Cell Res. 313:1181–1191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ryan HE, Poloni M, McNulty W, Elson D,
Gassmann M, Arbeit JM and Johnson RS: Hypoxia-inducible
factor-1alpha is a positive factor in solid tumor growth. Cancer
Res. 60:4010–4015. 2000.PubMed/NCBI
|
|
14
|
Kuwai T, Kitadai Y, Tanaka S, Elson D,
Gassmann M, Arbeit JM and Johnson RS: Expression of
hypoxia-inducible factor-1alpha is associated with tumor
vascularization in human colorectal carcinoma. Int J Cancer.
105:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kimura S, Kitadai Y, Tanaka S, Kuwai T,
Hihara J, Yoshida K, Toge T and Chayama K: Expression of
hypoxia-inducible factor (HIF)-1alpha is associated with vascular
endothelial growth factor expression and tumour angiogenesis in
human oesophageal squamous cell carcinoma. Eur J Cancer.
40:1904–1912. 2004. View Article : Google Scholar
|
|
16
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng H, Takahashi H, Murai Y, Cui Z,
Nomoto K, Niwa H, Tsuneyama K and Takano Y: Expressions of MMP-2,
MMP-9 and VEGF are closely linked to growth, invasion, metastasis
and angiogenesis of gastric carcinoma. Anticancer Res.
26:3579–3583. 2006.PubMed/NCBI
|
|
18
|
Ji Z, Long H, Hu Y, Qiu X, Chen X, Li Z,
Fan D, Ma B and Fan Q: Expression of MDR1, HIF-1alpha and MRP1 in
sacral chordoma and chordoma cell line CM-319. J Exp Clin Cancer
Res. 29:1582010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schweizer MS, Schumacher L and Rubin MA:
Constructing tissue microarrays for research use. Curr Protoc Hum
Genet. Chapter 10(Unit 10)7–Feb. 2004, PubMed/NCBI
|
|
20
|
Zhong H, De Marzo AM, Laughner E, Lim M,
Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons
JW: Overexpression of hypoxia-inducible factor 1alpha in common
human cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
21
|
Xiang ZL, Zeng ZC, Fan J, Tang ZY, Zeng HY
and Gao DM: Expression profiling of fixed tissues identified
hypoxia-inducible factor-1 alpha, VEGF, and matrix
metalloproteinase-2 as biomarkers of lymph node metastasis in
hepatocellular carcinoma. Clin Cancer Res. 17:5463–5472. 2011.
View Article : Google Scholar
|
|
22
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis - correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rankin EB and Giaccia AJ: The role of
hypoxia-inducible factors in tumorigenesis. Cell Death Differ.
15:678–685. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bussolino F, Mantovani A and Persico G:
Molecular mechanisms of blood vessel formation. Trends Biochem Sci.
22:251–256. 1997. View Article : Google Scholar
|
|
26
|
Chen KW, Yang HL, Lu J, Wang GL, Ji YM, Wu
GZ, Zhu LF, Liu JY, Chen XQ and Gu YP: Expression of vascular
endothelial growth factor and matrix metalloproteinase-9 in sacral
chordoma. J Neurooncol. 101:357–363. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Naka T, Kuester D, Boltze C, Schulz TO,
Samii A, Herold C, Ostertag H and Roessner A: Expression of matrix
metallo- proteinases-1, -2, and -9; tissue inhibitors of matrix
metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen
activator; and plasminogen activator inhibitor, type I in skull
base chordoma. Hum Pathol. 39:217–223. 2008. View Article : Google Scholar
|
|
28
|
Naka T, Boltze C, Kuester D, Schulz TO,
Samii A, Herold C, Ostertag H and Roessner A: Expression of matrix
metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase
plasminogen activator in non-skull base chordoma. Am J Clin Pathol.
122:926–930. 2004. View Article : Google Scholar : PubMed/NCBI
|
